kilat 333KT-333 is the first heterobifunctional degrader against an undrugged transcription factor to enter clinical development. In November 2021, Kymera announced that multiple abstracts were39 Followers, 106 Following, 20 Posts - Luvena Kilat (@luvena_kilat333) on : Bettingan Kini Lancar & Akurat